Cost-Effectiveness of Ruxolitinib for The Treatment of Myelofibrosis In Finland. Economic Evaluation Based on Finnish Auria Biobank Data on Health Care Resource Utilization - UTU Research Portal

Other publication

Cost-Effectiveness of Ruxolitinib for The Treatment of Myelofibrosis In Finland. Economic Evaluation Based on Finnish Auria Biobank Data on Health Care Resource Utilization

Authors: Hahl J, Kurki S, Miettinen T, Snicker K

Publication year: 2015

Journal:: Value in Health

Volume: 18

Issue: 7

First page : A669

Number of pages: 1

ISSN: 1098-3015

DOI: https://doi.org/10.1016/j.jval.2015.09.2446

Abstract

Myelofibrosis (MF) is a rare and life-threatening myeloproliferative disorder characterized by progressive scarring of the bone marrow and a number of severely debilitating symptoms. The objective of this analysis was to estimate cost-effectiveness of ruxolitinib (RUX) in a treatment of MF patients compared with best available therapy (BAT) in Finland.